194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial

• Victor Moreno,
• Ignacio Melero,
• Michael Millward,
• Tracy Liu,
• Rafał Stec,
• Erika Hamilton,
• Ana Maria Arance,
• Jennifer S Michaelson,
• Laura Liu,
• Alexander I Spira,
• Judy S Wang,
• Irina M Shapiro,
• Kerry A Whalen,
• Jeffrey A Jones

Affiliations

Victor Moreno

Oncology Data Analytics Programme, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain

Ignacio Melero

17 Clinica Universidad de Navarra-Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain

Michael Millward

21 Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Western Australia, Australia

Tracy Liu

2 Faculty of Pharmacy, University of British Columbia, Vancouver, British Columbia, Canada

Rafał Stec

Department of Oncology, Medical University of Warsaw, Warsaw, Poland

Erika Hamilton

3Sarah Cannon Research Institute, Tennessee Oncology, Breast and Gynecologic Cancer Research, Nashville, USA

Ana Maria Arance

6Hospital Clínic Barcelona, Barcelona, Spain

Jennifer S Michaelson

Cullinan Oncology Inc, Cambridge, Massachusetts, USA

Laura Liu

Bristol Myers Squibb Co, Princeton, New Jersey, USA

Alexander I Spira

2Next Oncology, Fairfax, VA, USA

Judy S Wang

9Florida Cancer Specialists/SCRI, Sarasota, FL, USA

Irina M Shapiro

1Cullinan Oncology, Inc., Cambridge, MA, USA

Kerry A Whalen

1Cullinan Oncology, Inc., Cambridge, MA, USA

Jeffrey A Jones

1Cullinan Oncology, Inc., Cambridge, MA, USA